Pacira BioSciences Faces Proxy Fight as DOMA Challenges Board
Event summary
- Pacira BioSciences is facing a proxy contest, with DOMA Perpetual Capital Management nominating three director candidates.
- DOMA's nomination comes after 12 meetings with Pacira's Board and management, with no new strategic insights shared.
- Pacira touts progress on its '5x30' strategy, including 6.2% EXPAREL volume growth in 2025 and record gross margins of 81%.
- Pacira executed $150 million in common stock repurchases in 2025, reducing outstanding shares from 47 million to 41 million.
- The 2026 Annual Meeting date has not been announced, and no shareholder action is required at this time.
The big picture
The proxy fight highlights a growing trend of activist investors targeting biopharma companies, particularly those perceived as underperforming or lacking clear strategic direction. DOMA's challenge suggests a lack of confidence in Pacira's current management and board's ability to unlock shareholder value, despite the company's claims of progress. The outcome will likely set a precedent for future shareholder activism within the pain management sector.
What we're watching
- Governance Dynamics
- The outcome of the proxy contest will reveal the extent of shareholder dissatisfaction with Pacira’s current strategy and board composition, potentially influencing future governance decisions.
- Execution Risk
- Pacira's ability to deliver on the ambitious goals outlined in its '5x30' strategy will be critical, and any setbacks could embolden activist investors.
- Pipeline Progress
- The upcoming data releases for PCRX-201 and iovera will be key catalysts for the stock, and their success will determine the long-term viability of Pacira’s pipeline.
Related topics